The Global Health Body Sounds Warning Over Critical Lack of Weight-Loss Injections
Less than a tenth of people that would benefit from GLP-1 drugs like Wegovy can access them, caution the World Health Organization as it releases its initial recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for broader and more equitable availability to this class of drugs.
Per forecasts, over two billion are projected to be obese by 2030 without intervention.
"The latest guidelines recognises that obesity is a lifelong illness that can be addressed with holistic and lifelong care," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key hurdles to broad access to the treatments that can assist patients in reducing considerable body mass, says the agency.
Weight-Loss Drug Supply Crisis
Even in the present most favorable outlook, the production of such drugs would only suffice for about 100 million people – under 10% of the global need, according to the WHO.
The advice calls on governments and firms to increase availability, through approaches including voluntary licensing.
Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in several countries in 2026.
The Way Obesity Injections Work
GLP-1 drugs replicate a natural hormone to slow digestion, curb appetite and boost satiety so people reduce food intake.
Individuals commonly see weight reduction in the initial weeks of beginning the weekly injections.
Studies indicates users may regain a significant portion after a year of discontinuing the medication, because their usual appetite resume.
To be carrying excess weight raises your chance for developing medical conditions, such as diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects individuals in countries worldwide and was linked to millions of deaths worldwide in 2024, as per the WHO.
